Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- antibodies HDL high-density lipoproteins WB western blots polypeptide immunoblotting blotting A-I Apo A1 A-1 apopipoproteins
- Product Overview:
ApoA1 is a major protein component in high-density lipoproteins (HDLs). It acts as an acceptor for sequential transfers of phospholipids and free cholesterol from peripheral tissues and transports cholesterol to the liver and other tissues for excretion and steroidogenesis.{14038} Serum ApoA1 levels are inversely related to the risk of developing atherosclerosis.{14039} Loss-of-function mutations are causes of diseases such as HDL deficiency type 1 (or Tangier disease) and type 2 (familial hypoalphalipoproteinemia), and systemic non-neuropathic amyloidosis.{14037,14040} Liver and small intestine are two main sources of the protein. ApoA1 is comprised of a single polypeptide chain of 243 amino acid residues with an estimated molecular weight of 28 kDa. Cayman’s ApoA1 Monoclonal Antibody detects the protein from diluted human plasma (?10 µg total protein) by western blotting. Western blotting of recombinant ApoA1 samples suggest a detection limit of 5 ng.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.